Consistently, liver-specific HK2 knockout (KO) mice showed a reduced incidence of DEN-induced HCC, an ameliorated oxygen consumption rate (OCR), and a response to Sorafenib, a multikinase inhibitor exploited as a pharmacological approach in advanced HCCs [141]. This evidence concerns the gene HK2 and hepatocellular carcinoma.